

RECORD COPY

PC

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For Filing Office use only	
PCT/US 00/24597	
International Application No.	
8 SEP 2000	(06 04 00)
International Filing Date	
PCT INTERNATIONAL APPLICATION FOR PATENT	
Applicant's or agent's file reference (if desired) (12 characters maximum) 2653/37	

Box No. I TITLE OF INVENTION POLYSIALIC ACID-KLH CONJUGATE VACCINE	
Box No. II APPLICANT	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	
SLOANE-KETTERING INSTITUTE FOR CANCER RESEARCH 1275 York Avenue New York, NY 10021 US	
<input type="checkbox"/> This person is also inventor.	
Telephone No.	
Facsimile No.	
Teleprinter No.	
State (that is, country) of nationality: US	State (that is, country) of residence: US
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	
LIVINGSTON, Philip O. 156 E. 79th St. New York, NY 10021 US	
This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)	
State (that is, country) of nationality: US	State (that is, country) of residence: US
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on a continuation sheet.	
Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE	
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: <input checked="" type="checkbox"/> agent <input type="checkbox"/> common representative	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	
DELUCIA, Richard L. WILSON, M. Lisa CASSON, Larry P. KENYON & KENYON One Broadway New York, NY 10004, US	
Telephone No. 212-425-7200	
Facsimile No. 212-425-5288	
Teleprinter No.	
<input type="checkbox"/> Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.	

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet is not to be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

RAGUPATHI, Govindasnami
303 E. 60th St.
New York, NY 10021
US

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
IN

State (that is, country) of residence:
US

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)


National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> LC Saint Lucia |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> LK Sri Lanka |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LR Liberia |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MA Morocco |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> MZ Mozambique |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:



Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claim indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application: regional Office	international application: receiving Office
item (1) 08/09/00 99 444 08 September 2000	09/392,097	US		
item (2)				
item (3)				
<input checked="" type="checkbox"/> The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1) <small>* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.</small>				
Box No. VII INTERNATIONAL SEARCHING AUTHORITY				
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):		Request to use results of earlier search: reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):		
ISA/us		Date (day/month/year) Number Country (or regional Office)		
Box No. VIII CHECK LIST: LANGUAGE OF FILING				
This international application contains the following number of sheets:		This international application is accompanied by the item(s) marked below:		
request : 4		1. <input checked="" type="checkbox"/> fee calculation sheet		
description (excluding sequence listing part) : 22		2. <input type="checkbox"/> separate signed power of attorney		
claims : 11		3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:		
abstract : 1		4. <input type="checkbox"/> statement explaining lack of signature		
drawings : 0		5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):		
sequence listing part of description : 38		6. <input type="checkbox"/> translation of international application into (language):		
Total number of sheets : 38		7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material		
		8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form		
		9. <input type="checkbox"/> other (specify):		
Figure of the drawings which should accompany the abstract:		Language of filing of the international application: English		
Box No. IX SIGNATURE OF APPLICANT OR AGENT				
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).				
 Lawrence P. Casson Agent for Applicant				

For receiving Office use only		(08-09-00)	
1. Date of actual receipt of the purported international application:	526 Rec'd PCT 08 SEP 2000	2. Drawings:	
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		<input type="checkbox"/> received:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):		<input type="checkbox"/> not received:	
5. International Searching Authority (if two or more are competent): ISA/us	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.		

For International Bureau use only	
Date of receipt of the record copy by the International Bureau:	28 SEP 2000
	28.09.00

POLYSIALIC ACID-KLH CONJUGATE VACCINE

FIELD OF THE INVENTION

Polysialic acid is a tumor antigen found on the surface of small cell lung cancer (SCLC) and neuroblastoma cells. Normally, however, it is recognized as a self antigen by the immune system and ignored. In accordance with this invention, compositions of long chain polysialic acid polymers covalently conjugated to an immunogenic carrier and mixed with a saponin have been discovered which are effective immunogens to produce high titer antibodies useful for treating SCLC and neuroblastoma. In addition to the compositions, this invention provides active and passive immunization methods for treating SCLCs and neuroblastomas, as well as metastases of these cancers.

BACKGROUND OF THE INVENTION

In the United States, lung cancer remains the leading cause of cancer death in men, and has surpassed breast cancer as the leading cause of death in women. Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancer cases, and is the fifth leading cause of death from cancer (Wingo et al., 1995). Distant metastases are present in more than two-thirds of patients with SCLC at diagnosis, and in the absence of treatment, tumor progression is rapid, with a median survival of only 2 to 4 months. However, SCLC is responsive to chemotherapy, with over 80% of patients with limited stage disease (LD) and over 60% of patients with extensive stage disease (ED) achieving a major response to treatment. Despite these results, relapses are common, and most patients die within two years of their diagnosis. The median survival of patients with LD is 14-20 months, and those with ED is 8-12 months. Over the past decade, no additional therapy has been shown to improve overall survival, and standard therapy is observation alone for patients who have achieved a major response after 4 to 6 cycles of chemotherapy. Hence, new approaches to adjuvant therapy are needed.

Antibodies produced by B cells are the primary mechanism for the elimination of circulating pathogens from the bloodstream. They can cause rejection of allografts by both acute and chronic mechanisms. Antibodies induce destruction of cells by several mechanisms including opsonification and removal by the reticuloendothelial system, complement mediated lysis, and antibody-dependent cell mediated lysis. Thus, antibodies appear ideally suited for eradication of circulating tumor cells and micrometastases in the adjuvant setting (Livingston, 1995).

A study using monoclonal antibodies (mAbs) against polysialic acid demonstrated that this molecule is distributed on SCLC and neuroblastoma cells (Zhang, 1997). For example, polysialic acid was detected on 6 of 6 SCLCs and 5 of 5 neuroblastomas but not on any of the other cancer cells tested. Moreover, polysialic acid (as detected by mAbs 735 and NP-4) had a more restricted distribution on normal tissues than most of the other antigens, being detectable in grey matter of the brain by 735 but not NP-4, and in bronchial epithelia and some alveolar pneumocytes by both mAbs. NP-4 also showed some reactivity with secretory epithelia of stomach, colon and pancreas. While the possibility exists that immunization with polysialic acid could induce an autoimmune response against various subpopulations of cells, expression of polysialylated proteins on normal tissues seems to be minimal and in privileged sites. In fact, individuals having high titer antibodies against these polysialic acid antigens and some patients with paraproteins against polysialic acid have been identified, with no evidence of autoimmunity (Pon et al., 1997).

Polysialic acid chains associated with certain cancers have been characterized and generally contain 14 or more sialic acid units linked by alpha-2,8 linkages. These long polysialic acid chains are covalently attached to the extracellular regions of the neural cell adhesion molecule (N-CAM) by post-translational modification. The median number of sialic acid units in the polymers may be as high as 50. The embryonal form of N-CAM, modified with long sialic acid polymers, is found on the great majority of neuroblastomas and SCLC cells (Troy, 1992; Zhang et al., 1997). Long polysialic acid chains are also found in developing neural tissues of the fetus. Apart from mammalian cells, long polysialic acid chains are found to be associated

with the outer membrane of *Escherichia coli* K1 and *Neisseria meningitidis* Group B (Rougon et al., 1986). The difference between polysialic acid chains of bacteria and embryonal N-CAM relative to polysialic acid chains attached to N-CAM in mature tissue is the number of sialic acid units in the chain which may average 50 or more for the bacterial/embryonal form but fewer than 8 for the mature form. During post-natal maturation, the embryonal form is down-regulated (Friedlander et al., 1985), but can be found to be expressed on tumor cells (Roth et al., 1988; Komminoth et al., 1991) and certain types of normal cells (see, e.g., Husmann et al., 1989). For reasons that appear related to the secondary structure assumed by these longer polysialic acid chains, a series of monoclonal antibodies including mAbs 735 and NP-4 react strongly with embryonal neural tissue, neuroblastomas and SCLC tissues but only weakly or not at all with most normal tissues, which are known to express N-CAM with the shorter mature form polysialic acid (Hayrinen et al., 1995). Thus, the presence of antigenically distinct long polysialic acid chains on SCLC cells and neuroblastomas and the limited distribution of long polysialic acid chains in mature tissue suggests that it is an excellent target for immunotherapy.

The poor immunogenicity of polysialic acid is borne out by studies of high molecular weight polysaccharides extracted from group B strains of *N. meningitidis* (MenB) of which sialic acid was the major constituent (Gotschlich et al., 1969). In a study where antibody responses to group B polysaccharides were tested in human volunteers, out of 51 men tested, only one showed a confirmed rise in antibody (Wyle et al., 1972). On the basis of rabbit studies using MenB polysaccharide mixed with various adjuvants, only one of four volunteers immunized with MenB polysaccharide mixed with influenza vaccine developed a significant increase in antibody titer (Wyle et al., 1972). MenB polysaccharides coupled to tetanus toxoid failed to elicit polysaccharide specific antibodies in rabbits and mice (Jennings and Lugowski, 1981) and those antibodies actually produced were specific for the area of coupling between the MenB polysaccharide and the tetanus toxoid, rather than for the polysaccharide itself. To increase immunogenicity, *N. meningitidis* group B polysaccharides were modified by *N*-propionylation prior to immunization (Jennings et al., 1986).

However, not all of these antibodies raised against *N*-propionylated MenB polysaccharide were specific for native MenB polysaccharide (Hayrinen et al., 1995). Many antibodies reacted with propionyl moiety. Accordingly, there remains a need for an immunogen and a method to induce an immune response against polysialic acid linked to N-CAM.

SUMMARY OF THE INVENTION

This invention is directed to an immunogenic composition comprising an α -(2-8)-polysialic acid-carrier conjugate and a saponin, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number of sialic acid units in each of the polymers is at least about 10. The polysialic acid polymers can also be modified to increase immunogenicity. Modifications include, but are not limited to, *N*-acylation and *N*-propionylation. Polysialic acid polymers have at least about 10 sialic acid units in order to stimulate immunity against polysialic acid polymers of the type found attached to embryonal N-CAM and can comprise as many as 200 or more sialic acid units. Polysialic acid polymers of the invention which are obtained from bacteria can average about 50 to 100 subunits or more and have a molecular weight of about 10,000 or more. Preferred immunogenic carriers include keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Preferred saponins are QS-21 and the semi-synthetic saponin GPI 0100.

Another aspect of the invention is directed to compositions useful as vaccines comprising amounts of the immunogenic compositions of the invention effective to induce antibodies specific for polysialic acid moieties of embryonal neural cell adhesion molecule (N-CAM) and a pharmaceutically-acceptable vehicle. The preferred adjuvant is a saponin and more preferably is QS-21 or GPI 0100.

The invention also provides a method for stimulating antibodies specific for polysialic acid of embryonal N-CAM by administering an amount of an immunogenic composition of the invention sufficient to stimulate antibodies specifically reactive

with embryonal N-CAM. Such antibodies are also reactive with SCLC or neuroblastoma cells having long chain polysialic acids.

Yet another aspect of the invention is directed to a method of treating SCLC or neuroblastoma in a subject or a patient by administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and adjuvant in amount effective to ameliorate the cancer or neuroblastoma wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier. This method is useful for further treatment of patients who have previously undergone primary treatment for SCLC or neuroblastoma (e.g., tumor removal and/or one or more rounds of chemotherapy). Similarly, this method can be used to treat metastases of SCLC or neuroblastoma. The preferred carrier used in this method is KLH and the preferred adjuvant is a saponin.

A still further aspect of this invention relates to a method of stimulating immunity against group B *N. meningitidis* or *E. coli* K1 which comprises administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and saponin in an amount effective to stimulate immunity against group B *N. meningitidis* or *E. coli* K1, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number of sialic acid units in each of the polymers is at least about 10.

The present invention further provides a method of passive immunization for treating SCLC or neuroblastoma in a subject by administering human or humanized antibodies specific for embryonal N-CAM to the subject in an amount effective to ameliorate the SCLC or neuroblastoma. Such antibodies can be administered prior to, concurrent with or after the subject has undergone a primary treatment for SCLC or neuroblastoma and is also useful for treating metastases of SCLC or neuroblastoma.

In yet another embodiment, the invention is directed to a method of passively immunizing a subject to treat or ameliorate infection caused by group B

N. meningitidis or *E. coli* KI using antibodies raised in response to compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

5 The compositions of the invention comprise polysialic acid conjugated to an immunogenic carrier and a saponin, the amounts of each being effective to stimulate or enhance antibody production in a human subject. These compositions can be formulated as vaccines by admixture with one or more pharmaceutically acceptable vehicles.

10 Polysialic acid polymers of the invention are substantially homopolymers of sialic acid of sufficient length to stimulate the production of antibodies which bind to long chain polysialic acid. Long chain polysialic acid consists of 10 or more sialic acid subunits. This is in contrast to polysialic acid present on normal cells which generally consist of 8 or fewer sialic acid units. It has been determined that the
15 affinity of certain known monoclonal antibodies which bind to polysialic acid is significantly reduced when the polymer length is 8 sialic acid units or fewer. Such antibodies bind more efficiently when the polymer length is 10 or more. It has been suggested that binding of such antibodies requires that the polysialic acid polymer be in an extended conformation which is available only as the chain length increases
20 beyond 8 sialic acid units. Preferred polysialic acid polymers contain 14 or more sialic acid units and can have up to about 200 sialic acid units. Polysialic acids obtained from bacteria typically can have a molecular weight of at least about 10,000 and can contain at least about 50 sialic acid units. Polysialic acid polymers can be modified to increase immunogenicity (e.g., N-propionylated α -(2-8)-polysialic acid).

25 In accordance with the invention, the amount of polysialic acid in an immunogenic composition used for immunization is between about 0.1 μ g and about 1000 μ g, and preferably is between about 1 μ g and 100 μ g and more preferably is about 30 μ g. Hence, the amount of polysialic acid conjugate to administer depends on the total amount of sialic acid units present in the polysialic acid polymers
30 conjugated to the carrier. The amount carrier can be determined by the conjugation

ratio of the polysialic acid to the carrier. For example, for conjugates having polysialic acid moieties linked to KLH, the molar ratio of polysialic acid to KLH ranges from about 50 to 1 to about 250 to 1. The molar ratio can be about 25 to 1 to about 1000 to 1. Where polysialic acid moieties are linked to small immunogenic carrier molecules, the molar ratio of polysialic acid to carrier can be less than 25.

As used herein, "immunogenic carrier" means a molecule which can initiate T lymphocyte activation that accompanies an antibody response. Immunogenic carriers have determinants that stimulate helper T cells to secrete cytokines which activate and stimulate proliferation of antibody-producing B cells. Hence, to stimulate or enhance an antibody response against an antigen of interest, particularly with poor immunogens, the antigen can be covalently linked (i.e., conjugated) to such immunogenic carriers. An immunogenic carrier of the invention can be a protein or portion of a protein which, when conjugated to polysialic acid, stimulates or enhances antibody production against the polysialic moieties in the subject. Examples of immunogenic carrier proteins are KLH and BSA. Immunogenic carriers also include polypeptides that are promiscuous class II activators (see, e.g., Panina-Bordignon et al., 1989) to which polysialic acid can be conjugated. In some cases, the number of polysialic acid polymers that can be conjugated to a polypeptide will not be large, but if the polypeptide carrier molecule is a particularly good promoter of a class II immune response, a sufficient immune response to polysialic acid can be obtained. In a preferred embodiment, the carrier is KLH or a derivative thereof. Conjugate linkages are made by well known methods.

In addition to immunogenic proteins and polypeptides which comprise a T cell epitope, carriers can also be constructs to which other immunogenic moieties (e.g., cytokines, polypeptides bearing T cell epitopes, etc.) can be linked. Branched constructs such as lipo-thioester and branched polylysine allow for multiple covalent linkages of such immunogenic moieties as well as conjugation of multiple polysialic acid polymers. Carriers further include proteins and polypeptides which have been modified by the covalent addition of immunogenically active moieties.

Polysialic acid-carrier conjugates are formulated with the adjuvant saponin to form the compositions of the invention. Saponins are immunological adjuvants that promote non-specific immune responses. The saponins in the compositions of the invention are present in an amount from about 1 μg to about 2000 μg . Saponins include semi-synthetic and synthetic saponins. In a preferred embodiment, the adjuvant is a saponin derived from the bark of a *Quillaja saponaria* Molina tree. A particularly preferred adjuvant is QS-21. QS-21 is preferably present in an amount between about 50 μg and about 500 μg or between about 50 μg and about 200 μg and more preferably in an amount of about 100 μg . Other saponins from *Quillaja saponaria* Molina may also be used, as well as saponins from other plant sources. Another example of a saponin source is *Saponaria officinalis*. The monosaccharide composition, molecular weight, adjuvant effect and toxicity for a series of saponins has been described (Kensil et al., 1991). A second particularly preferred adjuvant is the semi-synthetic saponin GPI 0100. GPI 0100 is preferably present in an amount between about 10 μg and about 2000 μg or between about 100 μg and about 2000 μg or between about 100 μg and about 1000 μg and more preferably in an amount of about 500 μg to about 1000 μg .

The ratio of polysialic acid and adjuvant used in compositions of the invention can vary. One of ordinary skill in the art can readily determine the effective amounts of conjugated polysialic acid to be used for immunization. Positive immune responses are indicated, for example, by an increased titer of antibodies specific for the embryonal form of N-CAM or by increased complement mediated lysis of cells having long chain polysialic acid on the cell surface (e.g. H345 cells) by immune sera relative to preimmune sera.

Vaccines of the invention comprise the compositions of the invention and a pharmaceutically acceptable vehicle. The vaccines can be administered intradermally, subcutaneously, intramuscularly or by any other suitable route for eliciting an immune response. For the purposes of the invention, "pharmaceutically acceptable vehicle" means any of the standard pharmaceutical vehicles. Examples of suitable vehicles are well known in the art and include, but are not limited to, any of the standard vehicles

such as phosphate buffered saline, phosphate buffered saline containing Polysorb,
water, emulsions such as oil/water emulsion, and various types of wetting agents. In a
preferred embodiment, vaccines of the invention are for administration to a human.
Alternatively, a vaccine can be administered to any animal to induce the formation of
5 antibodies which bind to a polysialic acid moiety of embryonal N-CAM or for
producing humanized antibodies.

The invention further provides a method of stimulating the production of
antibodies specific for polysialic acid moieties on N-CAM (or on bacteria carrying
such moieties) in a subject which comprises administering a sufficient amount of a
10 composition of the invention to stimulate antibody production. Stimulating antibody
production means inducing the production of antibodies which bind to long-chain
polysialic acid polymers in a subject wherein such antibodies were previously
undetectable or detectable at only a low level or titer. Stimulation of antibody
production as used herein includes producing increased amounts of polysialic acid-
15 specific antibodies or antibodies with increased affinity for polysialic acid, or both.

Preferably, immunization with a composition of the invention is performed
using multiple injections administered over a time course which is selected to
maximize the titer and/or function of induced anti-polysialic acid antibodies.
However, any suitable immunization regimen can be used. In a preferred
20 embodiment, a composition of the invention for human administration comprises
KLH, or a derivative thereof, conjugated to polysialic acid and mixed with the
adjuvant saponin. The saponin is preferably QS-21.

Antibody titers in sera of immunized subjects can be determined by ELISA or
by any other assay to measure antibodies as well known to one of skill in the art. One
25 way to examine the function of such antibodies is to measure their ability to bind to
polysialic acid on the surface of cells. For example, dilutions of antisera from
immunized subjects can be added to cultured H345 cells, which express long chain
polysialic acid polymers, and antibodies in the antisera detected with secondary
antibodies which bind specifically to constant domains of the test antibodies. The
30 secondary antibodies can be labeled, for example with an enzyme or a fluorescent tag.

A measure of the degree to which detectable label is associated with the H345 cells is a measure of the ability of induced antibodies to bind to polysialic acid on the surface of a cell. Another way to test antisera from immunized subjects is to add serial dilutions of antisera, together with human complement, to cultured H345 cells and observe killing of the H345 cells. Other ways to test for binding and function of anti-polysialic acid antibodies raised by immunization with compositions of the invention will be evident to those of ordinary skill in the art.

Another aspect of this invention provides a method of treating SCLC or neuroblastoma in a subject by administering to the subject an amount of a composition of the invention effective to ameliorate, reduce or otherwise treat the SCLC or neuroblastoma. In accordance with the invention, adjuvants other than saponin can be used in this method. For example, adjuvants which can be substituted for, or utilized in addition to, saponin include, but are not limited to, alum, oil-in-water emulsions, complete or incomplete Freund's Adjuvant, non-ionic block copolymers (e.g., TiterMax™, L121, CRL 1005, etc.), adjuvant compositions which comprise bacteria derived substances such as monophospholipid A or cell wall skeleton (CWS), DNA having immunostimulatory CpG motifs and immunostimulatory cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 2 (IL-2). Other common adjuvants well known to those of ordinary skill in the art can also be used.

Ameliorating SCLC or neuroblastoma means elimination or reduction of remnants of operable tumors which remain following surgical excision or other means of obliterating the tumor (e.g., a primary treatment). Moreover, the method is also useful for treating (e.g., eliminating or reducing) metastases and circulating cells that may give rise to metastases. For example, by the time SCLC is detected and treated, distant metastases are present in more than two-thirds of patients. While immunotherapy can be used as an adjuvant to chemotherapy, the present invention contemplates using immunotherapy as a substitute for chemotherapy, particularly for cancer patients who are not responsive to chemotherapy. The present method may also aid in preventing relapses in patients who have undergone successful primary

507 415 20 11137

treatments. Hence, the present methods for treating SCLC or neuroblastoma are useful in a subject who has developed and been treated for SCLC or neuroblastoma and no longer displays any detectable signs of the cancer (i.e., a subject in remission).

Many ways are available to assess a patient's or subject's response to the immunotherapeutic methods of the invention. For example, methods of detecting cancerous cells or observing amelioration of the cancer are well known. An example of such a method is the detection of parathyroid hormone-related protein (PTHrP), which is expressed in a variety of human cancers including lung cancer, the COOH terminal of which is stable and measurable in urine (Nishigaki et al., 1999). Immunolabeling techniques are also available for detection of tumor cells in bone marrow of SCLC patients (Pelosi et al., 1999). Alternatively, reverse transcriptase polymerase chain reaction (RT-PCR) is increasingly used to detect small numbers of circulating tumor cells. Such cancer detection and surveillance techniques are applicable for both active and passive immunization methods.

Compositions of the invention can also be used to stimulate immunity against group B *N. meningitidis* or *E. coli* KI. As in methods described above, immunity can be shown by an increase in the titer and/or affinity of circulating antibodies capable of binding to the polysialic acid moieties on the embryonal form of N-CAM or to the polysialic acid moieties on the aforementioned bacteria. If necessary, increased titers of circulating antibodies can be maintained by a regular course of immunizations. However, following an initial course of vaccination, it is usually sufficient to administer booster vaccinations when needed to maintain the immune system in a state where it can respond to subsequent infection with a vigorous secondary immune response. The timing of administering booster vaccines can be determined by one of ordinary skill in the art.

A further aspect of the invention provides methods of passive immunization using antibodies obtained against the compositions of the invention. Such antibodies can be obtained, for example, by immunizing a subject with a composition of the invention and recovering sera from the subject. If desired the anti-polysialic acid antibodies can be further purified from the sera. It is well within the abilities of one

of average skill in the art to purify such antibodies from antisera of subjects that have been vaccinated with compositions of the invention, as well as to collect and immortalize B cells secreting anti-polysialic acid antibodies from such subjects.

Antibodies useful for treatment of humans may be obtained from other sources as

5 well. Methods for generating human and humanized antibodies are well known. For example, the binding site amino acid residues of a non-human antibody specific for polysialic acid which was obtained by immunizing an animal with a composition of the invention can be substituted into a human antibody to produce a chimeric antibody which is not foreign to the human immune system. Alternatively, transgenic animals
10 which comprise human Ig genes can be vaccinated with compositions of the invention to obtain polyclonal antisera specific for polysialic acid, or for the production of hybridomas which secrete human monoclonal antibodies which are specific for polysialic acid. For a review of such methods, see, e.g., Vaughan et al. (1998).

Antibodies obtained by such methods can be used for treatment of SCLC and
15 neuroblastoma immediately upon diagnosis and prior to the usual primary treatments. Such antibodies can also be administered to treat or prevent the formation of metastatic tumors concurrent with or following primary treatments.

The antibodies can also be administered in methods of passive immunization against group B *N. meningitidis* or *E. coli* K1. Such methods of treatment are
20 especially useful for treating patients who may have acquired such an infection but whose immune systems have not had sufficient time to respond to and to eliminate the infection. Passive immunization can, for example, reduce the severity and duration of the infection. Methods and routes of administration are well known to those of ordinary skill in the art. Examples and reviews of such methods are readily available
25 (see, e.g., Schirmacher *et al.*, 1996; Saltzman, 1993; Masuho, 1992; Hammarstrom and Smith, 1990).

Throughout this application, various publications, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, and patent applications in their entireties are hereby

incorporated by reference into this application to more fully describe the state of the art to which the present invention pertains.

It is to be understood and expected that variations in the principles of invention herein disclosed may be made by one skilled in the art and it is intended that
5 such modifications are to be included within the scope of the present invention.

Examples of the invention which follow are set forth to further illustrate the invention and should not be construed to limit the invention in any way.

EXAMPLE 1

Antigen Preparation

Polysialic acid preparation - Poly-2,8-N-acetylneuraminic acid (colominic acid) is supplied as a powder (Sigma Chemical Co., St. Louis, MO; Nacalai Tesque, Inc., Kyoto, Japan) which contains a single major species of about 30,000 molecular weight (a homopolymer from *E. coli* of over 50 sialic acid units) and multiple species of lower molecular weight. Prior to conjugation to KLH, long polysialic acid chains were purified from lower molecular weight chains by gel filtration chromatography. The polysialic acid was purified using a Sephacryl S-200 column (flow rate 1 ml/min; column dimensions 90 cm x 2.5 cm) and eluted with sterile PBS by Fast Performance Liquid Chromatography (FPLC). The long chain fraction was used directly for conjugation to KLH.

Conjugation of polysialic acid to KLH - Conjugation of polysialic acid to KLH (Intracel Corp., Rockville, MD) was accomplished by the periodate method which involves the reaction of sodium metaperiodate with the vicinal hydroxyl groups in the polysialic acid chain to form a dialdehyde at the end of each chain. The dialdehyde is reacted with free amino groups of KLH in aqueous solution to yield diamine linkages which in turn are stabilized by reaction with sodium cyanoborohydride.

Preparation of polysialic acid dialdehyde - All glassware was rinsed with distilled water and autoclaved prior to use. 10 mg of purified polysialic acid was dissolved in 1 ml sodium phosphate buffer. 2.5 mg of sodium metaperiodate (freshly prepared) was added and the solution was stirred at room temperature (25°C) for 90 minutes. At the end of the incubation period, 2.9 mg (46.6 μ mole) of ethylene glycol (2.6 μ l; 1.11 mg/ μ l) may be added to neutralize unreacted sodium metaperiodate and the solution stirred for 15 min. at 25°C. Whether neutralized or not, excess sodium metaperiodate was removed by passage over a Sephadex G-10 column equilibrated with PBS buffer. Fractions were collected at one minute intervals and those fractions shown to be positive by reaction with 0.2% resorcinol were combined.

Conjugation of polysialic acid dialdehyde to KLH - The polysialic acid dialdehyde was transferred to a sterile glass bottle containing 5 mg of sterile, pyrogen-free KLH (Intracel Corp., Rockville, MD) dissolved in PBS (5 mg/ml). The flask was rinsed two times with 2.5 ml of PBS, and these washes were added to the
5 KLH/polysialic acid dialdehyde mixture and allowed to incubate at 37°C for 60 minutes with gentle stirring. A 20 mg/ml solution of sodium cyanoborohydride (NaBH_3CN) in PBS was prepared and sterile filtered. 1 ml of the NaBH_3CN solution was added to the KLH/polysialic acid dialdehyde mixture and incubated at 37°C for
10 48 hr.

Purification of polysialic acid-KLH glycoconjugate - The contents of the polysialic acid-KLH reaction vial were loaded on a Sephacryl S-200 column (flow rate 1 ml/min; column dimensions 90 cm x 2.5 cm) and eluted with sterile saline. The fractions positive for both KLH and polysialic acid were combined and sterile filtered
15 with a 0.22 μm low protein-binding sterile, pyrogen-free filter and stored at -20°C.

Protein and sialic acid content were determined by BioRad protein assay and resorcinol reaction, respectively. QS-21 was added to yield 100 $\mu\text{g}/\text{ml}$ and the mixture was filtered through a 0.22 μm filter. Aliquots of 1 ml were added to sterile
20 2 ml vials (Nunc) and lyophilized, capped and stored at -30°C.

EXAMPLE 2

Immunization

CB6/F1 mice were immunized subcutaneously with KLH-conjugated polysialic acid and 10 μ g of QS-21 adjuvant. The amount of polysialic acid administered, as determined by reaction with resorcinol, was 3 μ g. The initial vaccination was followed by two identical booster vaccinations at one week intervals.

Blood was collected and the presence of antibodies capable of binding to sialic acid was determined in two ways. First, antibody titers were determined by ELISA for both IgG and IgM. Table 1 shows the titers of IgM and IgG in the serum of five mice immunized according to the above protocol and indicates the highest serum dilutions which yielded a signal in an ELISA assay using microtiter dishes coated with a polysialic acid-BSA conjugate. All 5 mice displayed significant increases in antibody titer for both IgM and combined IgG classes.

Table 1 Ab ELISA Titers Induced by Polysialic acid - KLH conjugate with QS-21				
Mouse Number	Preimmune Serum		Immune Serum	
	IgM	IgG	IgM	IgG
1	0	0	200	6,400
2	0	0	1,600	6,400
3	0	0	1,600	25,600
4	0	0	200	12,800
5	0	0	1,600	12,800

The capacity of the serum antibodies to bind to surface antigen of H345 tumor cells (ATCC catalog no. HTB-180) was also tested. H345 cells were incubated with serum preparations from the five immunized mice and with preimmune serum. IgG and IgM antibodies were determined using fluorescein isothiocyanate (FITC)-conjugated secondary reagents specific for the selected antibody classes. Antibody bound to the H345 cells was determined by measuring fluorescence with a fluorescence-activated cell sorter (FACS). As shown in Table 2, the results of the FACS analysis demonstrate that the sera of all five mice produced antibodies capable

of binding to polysialic acid on tumor cells. Furthermore, the antisera promoted complement-induced tumor cell lysis *in vitro*.

Table 2
Antisera Reactivity with Tumor Cells by FACS Analysis

Mouse Number	% Positive IgM	% Positive IgG
1	36.44	81.63
2	90.02	93.37
3	91.72	89.41
4	93.83	88.78
5	92.37	94.96
Preimmune Serum	8.25	10.28

EXAMPLE 3

Immunization

Patients having completed initial therapy for SCLC and having achieved either a complete or partial response to therapy without subsequent disease progression were immunized subcutaneously with 30 μ g of polysialic acid in polysialic acid-KLH conjugate and 100 μ g of QS-21 adjuvant or 30 μ g of N-propionylated polysialic acid in N-propionylated polysialic acid-KLH conjugate and 100 μ g of QS-21 adjuvant. Four vaccinations were administered at one week intervals. A fifth vaccination was then administered following a four week interval (week 8) and a sixth vaccination was administered after a further eight week interval (week 16). Peripheral blood (20 - 30 ml) was drawn immediately before each vaccination and 2 weeks after the fourth, fifth and sixth vaccinations (weeks 6, 10 and 18).

Antibody responses were measured as described above in Example 2. As measured by ELISA assay using microtiter dishes coated with a polysialic acid-BSA conjugate and blocked with human serum albumin, four patients showed significant IgM responses to the N-propionylated polysialic acid-KLH conjugate administered with QS-21 (Table 3).

Table 3
Ab ELISA Titers against Polysialic acid - BSA conjugate
Induced by Polysialic acid - KLH conjugate with QS-21
or N-propionylated Polysialic acid - KLH conjugate with QS-21

Vaccine	Patient	Median ELISA titer			
		IgM		IgG	
		Preimmune Serum	Immune Serum	Preimmune Serum	Immune Serum
PSA-KLH + QS-21	1	20	40	40	40
	2	10	10	20	20
	3	80	80	0	0
	4	0	20	0	0
	5	0	0	0	0
N-propionylated PSA-KLH + QS-21	1	10	320	0	0
	2	10	320	0	0
	3	40	1280	40	20
	4	10	20	0	0
	5	10	0	0	0
	6	0	80	0	40

H69 SCLC tumor cells (Carney et al., 1985; ATCC catalog no. HTB-180) were used to test the serum of immunized subjects for the presence of antibodies capable of binding to SCLC tumor cells (Table 4). Because preimmune sera usually shows binding to a variety of antigens present on the surface of the cells, a serum dilution was chosen for each subject which resulted in approximately 10% of H69 cells testing positive in FACS analysis with preimmune serum. This same dilution was applied to immune serum which was later obtained from that subject. The increases in % positive cells observed for immune sera as compared to preimmune sera should primarily reflect an increase in antibodies specific for polysialic acid displayed on H69 cells. In three subjects, the response to N-propionylated polysialic

acid-KLH conjugate plus QS-21 is detectable above the background level of serum antibodies which bind to other H69 antigens.

Table 4
Antisera Reactivity with Tumor Cells by FACS Analysis

Vaccine	Patient	Median Percent Positive Cells			
		IgM		IgG	
		Preimmune Serum	Immune Serum	Preimmune Serum	Immune Serum
PSA-KLH + QS-21	1	10	18	10	16
	2	10	8	11	12
	3	10	16	11	14
	4	10	6	11	15
	5	10	11	11	9
N-propionylated PSA-KLH + QS-21	1	11	48	11	14
	2	11	27	11	8
	3	10	15	10	24
	4	10	8	10	16
	5	11	10	11	5
	6	10	12	10	7

References

- Carney, D.N., Gazdar, A.F., Bepler, G., Guccion, J.G., Marangos, P.J.,
Moody, T.W., Zweig, M.H. and Minna, J.D. (1985) Establishment and identification
of small cell lung cancer cell lines having classic and variant features. *Cancer Res.*
45:2913-2923.
- Friedlander, D.R., Brackenbury, R. and Edelman, G.M. (1985) Conversion of
embryonic form to adult forms of N-CAM in vitro: results from de novo synthesis of
adult forms. *J. Cell Biol.* 101:412-419.
- Gotschlich, E.C., Liu, T.Y. and Artenstein, M.S. (1969) Human immunity to
the meningococcus. 3. Preparation and immunochemical properties of the group A,
group B, and group C meningococcal polysaccharides. *J. Exp. Med.* 129:1349-1365.
- Hammarstrom, L. and Smith, C.I. (1990) New and old aspects of
immunoglobulin application. The use of intravenous IgG as prophylaxis and for
treatment of infections. *Infection* 18:314-324.
- Hayrinen, J., Jennings, H., Raff, H.V., Rougon, G., Hanai, N.,
Gerardy-Schahn, R. and Finne, J. (1995) Antibodies to polysialic acid and its N-propyl
derivative: binding properties and interaction with human embryonal brain
glycopeptides. *J. Infect. Dis.* 171:1481-1490.
- Husmann, M., Pietsch, T., Fleischer, B., Weisgerber, C. and Bitter-Suermann,
D. (1989) Embryonic neural cell adhesion molecules on human natural killer cells.
Eur. J. Immunol. 19:1761-1763.
- Jennings, H.J. and Lugowski, C. (1981) Immunochemistry of groups A, B, and
C meningococcal polysaccharide-tetanus toxoid conjugates. *J. Immunol.*
127:1011-1018.
- Jennings, H.J., Roy, R. and Gamian, A. (1986) Induction of meningococcal
group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated
B polysaccharide-tetanus toxoid conjugate vaccine. *J. Immunol.* 137:1708-1713.
- Kensil, C.R., Patel, U., Lennick, M. and Marciani, D. (1991) Separation and
characterization of saponins with adjuvant activity from *Quillaja saponaria* Molina
cortex. *J. Immunol.* 146:431-437.
- Komminoth, P., Roth, J., Lackie, P.M., Bitter-Suermann, D. and Heitz, P.U.
(1991) Polysialic acid of the neural cell adhesion molecule distinguishes small cell
lung carcinoma from carcinoids. *Am. J. Pathol.* 139:297-304.

Livingston, P.O. (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. *Immunol. Rev.* 145:147-166.

5 Masuho, Y. (1992) Passive immunoprophylaxis with human monoclonal antibodies. *Biotechnology* 20:405-430.

Nishigaki, Y., Ohsakim, Y., Toyoshima, E. and Kikuchi, K. (1999) Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. *Clin. Cancer Res.* 5:1473-1481.

10 Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. *Eur. J. Immunol.* 19:2237-2242.

15 Pelosi, G., Pasini, F., Pavanel, F., Bresaola, E., Schiavon, I. and Iannucci, A. (1999) Effects of different immunolabeling techniques on the detection of small-cell lung cancer cells in bone marrow. *J. Histochem. Cytochem.* 47:1075-1088.

Pon, R.A., Lussier, M., Yang, Q. and Jennings, H.J. (1997) N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B neisseria meningitidis. *J. Exp. Med.* 185:1929-1938.

20 Roth, J., Zuber, C., Wagner, P., Taatjes D.J., Weisgerber, C., Heitz, P.U., Goridis, C. and Bitter-Suermann, D. (1988) Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor. *Proc. Natl. Acad. Sci. USA* 85:2999-3003.

25 Rougon, G., Dubois, C., Buckley, N., Magnani, J.L. and Zollinger, W. (1986) A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM. *J. Cell Biol.* 103:2429-2437.

Saltzman, W.M. (1993) Antibodies for treating and preventing disease: the potential role of polymeric controlled release. *Crit. Rev. Ther. Drug Carrier Syst.* 10:111-142.

30 Schirmacher, V., Umansky, V. and Rocha, M. (1996) Immunotherapy of metastases. *Curr. Top. Microbiol. Immunol.* 213:189-216.

Troy, F.A. 2d (1992) Polysialylation: from bacteria to brains. *Glycobiology* 2:5-23.

Vaughan, T.J., Osbourn, J.K. and Tempest, P.R. (1998) Human antibodies by design. *Nat. Biotechnol.* 16:535-539.

Wingo, P.A., Tong, T. and Bolden, S. (1995) Cancer statistics. *CA Cancer J. Clin.* 45:8-30.

5 Wyle, F.A., Artenstein, M.S., Brandt, B.L., Tramont, E.C., Kasper, D.L., Altieri, P.L., Berman, S.L. and Lowenthal, J.P. (1972) Immunologic response of man to group B meningococcal polysaccharide vaccines. *J. Infect. Dis.* 126:514-521.

10 Zhang, S., Cordon-Cardo, C., Zhang, H.S., Reuter, V.E., Adluri, S., Hamilton, W.B., Lloyd, K.O. and Livingston, P.O. (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. *Int. J. Cancer* 73:42-49.

WE CLAIM:

1. An immunogenic composition comprising an α -(2-8)-polysialic acid-carrier conjugate and a saponin, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.
2. The composition of Claim 1 wherein the α -(2-8)-polysialic acid polymer is modified to increase immunogenicity.
3. The composition of Claim 2 wherein modified α -(2-8)-polysialic acid polymer is N-propionylated α -(2-8)-polysialic acid.
4. The composition of Claim 1 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.
5. The composition of Claim 1 wherein the median number of sialic acid units in each of the polymers is at least about 50, or wherein each of the polymers has an average molecular weight of at least about 10,000.
6. The composition of Claim 1 wherein the immunogenic carrier is keyhole limpet hemocyanin (KLH), an immunogenic derivative of KLH, bovine serum albumin (BSA), an immunogenic derivative of BSA, a promiscuous class II activating polypeptide, or an immunogenic derivative of a promiscuous class II activating polypeptide.
7. The composition of Claim 1 wherein the immunogenic carrier is KLH.

8. The composition of Claim 7 wherein the molar ratio of polysialic acid to KLH in the conjugate is from about 25 to about 1000.
9. The composition of Claim 7 wherein the molar ratio of polysialic acid to KLH in the conjugate is about 200.
10. The composition of Claim 1 wherein the amount of saponin is from about 1 μg to about 2000 μg .
11. The composition of Claim 1 wherein said saponin is QS-21 or GPI 0100.
12. The composition of Claim 11 wherein QS-21 is in an amount from about 50 μg to about 500 μg .
13. The composition of Claim 12 wherein the amount of QS-21 is about 100 μg .
14. The composition of Claim 11 wherein GPI 0100 is in an amount from about 100 μg to about 2000 μg .
15. The composition of Claim 14 wherein the amount of GPI 0100 is from about 500 μg about 1000 μg .
16. The composition of Claim 1 wherein the amount of the polysialic acid of said conjugate is from about 1 μg to about 1000 μg .
17. The composition of Claim 1, wherein the amount of the polysialic acid of said conjugate is about 30 μg .

18. The composition of Claim 1 wherein said composition is capable of inducing antibodies specific for polysialic acid moieties of embryonal neural cell adhesion molecule (N-CAM).

19. An immunogenic composition comprising an α -(2-8)-polysialic acid-KLH conjugate and QS-21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of α -(2-8)-polysialic acid polymers covalently linked to KLH, and wherein the median number or sialic acid units in each of the polymers is 14 or greater.

20. A vaccine comprising an amount of the immunogenic composition of Claim 1 effective to induce antibodies specific for polysialic acid moieties of embryonal neural cell adhesion molecule (N-CAM) and a pharmaceutically acceptable vehicle.

21. A method for stimulating antibody production specific for polysialic acid of an embryonal N-CAM which comprises administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and saponin effective to stimulate antibodies reactive with embryonal N-CAM, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number or sialic acid units in each of the polymers is at least about 10.

22. The method of Claim 21 wherein the α -(2-8)-polysialic acid polymer is modified to increase immunogenicity.

23. The method of Claim 22 wherein modified α -(2-8)-polysialic acid polymer is N-propionylated α -(2-8)-polysialic acid.

24. The method of Claim 21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.

25. The method of Claim 21 wherein the median number of sialic acid units in each of the polymers is at least about 50, or wherein each of the polymers has an average molecular weight of at least about 10,000.

26. The method of Claim 21 wherein the immunogenic carrier is keyhole limpet hemocyanin (KLH), an immunogenic derivative of KLH, bovine serum albumin (BSA), an immunogenic derivative of BSA, a promiscuous class II activating polypeptide, or an immunogenic derivative of a promiscuous class II activating polypeptide.

27. The method of Claim 21 wherein the immunogenic carrier is KLH.

28. The method of Claim 27 wherein the molar ratio of polysialic acid to KLH in the conjugate is from about 25 to about 1000.

29. The method of Claim 27 wherein the molar ratio of polysialic acid to KLH in the conjugate is about 200.

30. The method of Claim 21 wherein the amount of saponin is from about 1 μg to about 2000 μg .

31. The method of Claim 21 wherein said saponin is QS-21 or GPI 0100.

32. The method of Claim 31 wherein QS-21 is in an amount from about 50 μg to about 500 μg .

33. The method of Claim 32 wherein the amount of QS-21 is about 100 μg .

34. The method of Claim 31 wherein GPI 0100 is in an amount from about 100 μg to about 2000 μg .

35. The method of Claim 34 wherein the amount of GPI 0100 is from about 500 μg to about 1000 μg .

36. The method of Claim 21 wherein the amount of polysialic acid of said conjugate is from about 1 μg to about 1000 μg .

37. The method of Claim 21 wherein the amount of polysialic acid of said conjugate is about 30 μg .

38. The method of Claim 21 wherein said composition comprises an α -(2-8)-polysialic acid-KLH conjugate and QS-21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of α -(2-8)-polysialic acid polymers covalently linked to KLH, and wherein the median number of sialic acid units in each of the polymers is 14 or greater.

39. A method of treating small cell lung cancer or neuroblastoma in a subject which comprises administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and adjuvant in amount effective to ameliorate said small cell lung cancer or neuroblastoma, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number of sialic acid units in each of the polymers is at least about 10.

40. The method of Claim 39 wherein the α -(2-8)-polysialic acid polymer is modified to increase immunogenicity.

41. The method of Claim 40 wherein the modified α -(2-8)-polysialic acid polymer is N-propionylated α -(2-8)-polysialic acid.

42. The method of Claim 39 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.

43. The method of Claim 39 wherein the median number of sialic acid units in each of the polymers is at least about 50, or wherein each of the polymers has an average molecular weight of at least about 10,000.

44. The method of Claim 39 wherein the immunogenic carrier is keyhole limpet hemocyanin (KLH), an immunogenic derivative of KLH, bovine serum albumin (BSA), an immunogenic derivative of BSA, a promiscuous class II activating polypeptide, or an immunogenic derivative of a promiscuous class II activating polypeptide.

45. The method of Claim 39 wherein the immunogenic carrier is KLH.

46. The method of Claim 45 wherein the molar ratio of polysialic acid to KLH in the conjugate is from about 25 to about 1000.

47. The method of Claim 45 wherein the molar ratio of polysialic acid to KLH in the conjugate is about 200.

48. The method of Claim 39 wherein said adjuvant comprises alum, a saponin, a semi-synthetic saponin-like molecule, CpG, GM-CSF, Freund's complete adjuvant, Freund's incomplete adjuvant or an oil-in-water emulsion.

49. The method of Claim 39 wherein said adjuvant is a saponin in an amount from about 1 μg to about 2000 μg .

50. The method of Claim 39 wherein said saponin is QS-21 or GPI 0100.

51. The method of Claim 50 wherein QS-21 is in an amount from about 50 μg to about 500 μg .

52. The method of Claim 51 wherein the amount of QS-21 is about 100 μg .

53. The method of Claim 50 wherein GPI 0100 is in an amount from about 100 μg to about 2000 μg .

54. The method of Claim 53 wherein the amount of GPI 0100 is from about 500 μg to about 1000 μg .

55. The method of Claim 39 wherein the amount of polysialic acid of said conjugate is from about 1 μg to about 1000 μg .

56. The method of Claim 39 wherein the amount of polysialic acid of said conjugate is about 30 μg .

57. The method of Claim 39 wherein said composition comprises an α -(2-8)-polysialic acid-KLH conjugate and QS-21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of α -(2-8)-polysialic acid polymers

covalently linked to KLH, and wherein the median number of sialic acid units in each of the polymers is 14 or greater.

58. The method of Claim 39, wherein the composition is administered after the subject has undergone primary treatment for the small cell lung cancer or neuroblastoma.

59. The method of Claim 39, wherein the composition is administered to treat metastasis of said small cell lung cancer or neuroblastoma.

60. A method of stimulating immunity against group B *N. meningitidis* or *E. coli* K1 which comprises administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and saponin in an amount effective to stimulate immunity against group B *N. meningitidis* or *E. coli* K1, wherein the α -(2-8)-polysialic acid-carrier conjugate comprises one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number of sialic acid units in each of the polymers is at least about 10.

61. The method of Claim 60 wherein the α -(2-8)-polysialic acid polymer is modified to increase immunogenicity.

62. The method of Claim 61 wherein the modified α -(2-8)-polysialic acid polymer is N-propionylated α -(2-8)-polysialic acid.

63. The method of Claim 60 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of one or more α -(2-8)-polysialic acid polymers covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.

64. The method of Claim 60 wherein the median number of sialic acid units in each of the polymers is at least about 50, or wherein each of the polymers has an average molecular weight of at least about 10,000.

65. The method of Claim 60 wherein the immunogenic carrier is keyhole limpet hemocyanin (KLH), an immunogenic derivative of KLH, bovine serum albumin (BSA), an immunogenic derivative of BSA, a promiscuous class II activating polypeptide, or an immunogenic derivative of a promiscuous class II activating polypeptide.

66. The method of Claim 60 wherein the immunogenic carrier is KLH.

67. The method of Claim 66 wherein the molar ratio of polysialic acid to KLH in the conjugate is from about 25 to about 1000.

68. The method of Claim 66 wherein the molar ratio of polysialic acid to KLH in the conjugate is about 200.

69. The method of Claim 60 wherein the amount of saponin is from about 1 μg to about 2000 μg .

70. The method of Claim 60 wherein said saponin is QS-21 or GPI 0100.

71. The method of Claim 70 wherein QS-21 is in an amount from about 50 μg to about 500 μg .

72. The method of Claim 71 wherein the amount of QS-21 is about 100 μg .

73. The method of Claim 70 wherein GPI 0100 is in an amount from about 100 μg to about 2000 μg .

74. The method of Claim 73 wherein the amount of GPI 0100 is from about 500 μg to about 1000 μg .

75. The method of Claim 60 wherein the amount of polysialic acid of said conjugate is from about 1 μg to about 1000 μg .

76. The method of Claim 60 wherein the amount of polysialic acid of said conjugate is about 30 μg .

77. The method of Claim 60 wherein said composition comprises an α -(2-8)-polysialic acid-KLH conjugate and QS-21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of α -(2-8)-polysialic acid polymers covalently linked to KLH, and wherein the median number of sialic acid units in each of the polymers is 14 or greater.

78. A method of treating small cell lung cancer (SCLC) or neuroblastoma in a subject which comprises administering human or humanized antibodies specific for embryonal N-CAM to the subject in an amount effective to ameliorate said small cell lung cancer or neuroblastoma.

79. The method of Claim 78 wherein the antibodies are administered prior to, concurrent with or after the subject has undergone primary treatment for said SCLC or neuroblastoma.

80. The method of Claim 78, wherein the antibodies are administered to treat metastasis of said SCLC or neuroblastoma.

81. A method of treating infection by group B *N. meningitidis* or *E. coli* K1 which comprises administering human or humanized antibodies specific for embryonal N-CAM to the subject in an amount effective to alleviate, reduce or eliminate said infection.

ABSTRACT

5 The invention relates to compositions and vaccines comprising conjugates of polysialic acid which are capable of inducing antibodies which react effectively with polysialic acid on the surface of cancer cells and to methods of treatment which involve the stimulation or use of such antibodies.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24597

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 39/385, 39/095; C07K 1/00

US CL :424/197.11, 250.1; 530/403, 395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/197.11, 250.1; 530/403, 395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JENNINGS et al. Induction of Meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunology. 01 September 1986, Vol. 137, No. 5, pages 1708-1713. See entire document.	1-81
Y	PON et al. N-propionylated group B Meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 02 June 1997, Vol. 185, No. 11, pages 1929-1938. See entire document.	1-81



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 NOVEMBER 2000

Date of mailing of the international search report

27 DEC 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MINH-TAM DAVIS

Telephone No. (703) 308-0916

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24597

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LIVINGSTON, P.O. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunological reviews. 1995, No. 145, pages 147-166. See entire document.	1-81
Y	HELLING et al. G _{D3} vaccines for melanoma: Superior immunogenicity of key hole limpet hemocyanin conjugate vaccines. Cancer Research. 01 January 1994, Vol. 54, pages 197-203. See entire document.	1-81
Y	ROTH et al. Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor. Proc. Natl. Acad. Sci. USA. May 1988, Vol. 85, pages 2999-3003. See entire document.	1-81

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24597

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG, WEST

search terms: polysialic acid, saponin, conjugate, key hole limpet hemocyanin, promiscuous class II activating polypeptide, qs-21, gpi

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

RECD 04 JAN 2001

WIPO

Applicant's or agent's file reference 2653/37	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US00/24597	International filing date (day/month/year) 08 SEPTEMBER 2000	(Earliest) Priority Date (day/month/year) 08 SEPTEMBER 1999 2000
Applicant SLOANE-KETTERING INSTITUTE FOR CANCER RESEARCH		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
2. ☐ Certain claims were found unsearchable (See Box I).
3. ☐ Unity of invention is lacking (See Box II).
4. With regard to the title,
- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☐ None of the figures.

PATENT COOPERATION TREATY

PCT

COMMUNICATION OF
INTERNATIONAL APPLICATIONS

(PCT Article 20)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as designated Office

Date of mailing:

30 May 2001 (30.05.01)

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:

PCT/US00/24597

International publication no.:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 17 July 2001 (17.07.01)	
International application No. PCT/US00/24597	Applicant's or agent's file reference 2653/37
International filing date (day/month/year) 08 September 2000 (08.09.00)	Priority date (day/month/year) 08 September 1999 (08.09.99)
Applicant LIVINGSTON, Philip, O. et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

30 March 2001 (30.03.01)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was.

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer H. Zhou Telephone No.: (41-22) 338.83.38
---	---